Evidence map›Paper›PMID 14747528›Full record

ArticleJournal of virology2004

Dramatic effects of 2-bromo-5,6-dichloro-1-beta-D-ribofuranosyl benzimidazole riboside on the genome structure, packaging, and egress of guinea pig cytomegalovirus.

Daniel E Nixon, Michael A McVoy

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Anti-CMV therapy, what next? A systematic review.Frontiers in microbiology · 2023
    Review
  4. Article
  5. Article
  6. Cytomegalovirus antivirals and development of improved animal models.Expert opinion on drug metabolism & toxicology · 2011
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Daniel E NixonDepartment of Medicine, Medical College of Virginia Campus of Virginia Commonwealth University, Richmond, Virginia 23298-0163, USA.
Michael A McVoy
Virginia Commonwealth University Medical Center · US

Funding

HUMAN CYTOMEGALOVIRUS DNA CLEAVAGE AND PACKAGINGR01AI046668 · NIAID · VIRGINIA COMMONWEALTH UNIVERSITY · PI MCVOY, MICHAEL A · 2001 to 2005
$1.2M
HERPESVIRUS GENOMIC CLEAVAGEK08AI001435 · NIAID · VIRGINIA COMMONWEALTH UNIVERSITY · PI NIXON, DANIEL E · 1997 to 2001
$249k
MECHANISMS OF HEPESVIRUS DNA CLEAVAGE/PACKAGINGR21AI043527 · NIAID · VIRGINIA COMMONWEALTH UNIVERSITY · PI MCVOY, MICHAEL A · 1998 to 1998
–
NIAID NIH HHS K08AI01435NIAID NIH HHS R01 AI046668NIAID NIH HHS R01AI46668NIAID NIH HHS R21AI43527
6 · The paper itself

Abstract

The halogenated benzimidazoles BDCRB (2-bromo-5,6-dichloro-1-beta-D-riborfuranosyl benzimidazole riboside) and TCRB (2,5,6-trichloro-1-beta-D-riborfuranosyl benzimidazole riboside) were the first compounds shown to inhibit cleavage and packaging of herpesvirus genomes. Both inhibit the formation of unit length human cytomegalovirus (HCMV) genomes by a poorly understood mechanism (M. R. Underwood et al., J. Virol. 72:717-715, 1998; P. M. Krosky et al., J. Virol. 72:4721-4728, 1998). Because the simple genome structure of guinea pig cytomegalovirus (GPCMV) provides a useful model for the study of herpesvirus DNA packaging, we investigated the effects of BDCRB on GPCMV. GPCMV proved to be sensitive to BDCRB (50% inhibitory concentration = 4.7 microM), although somewhat less so than HCMV. In striking contrast to HCMV, however, a dose of BDCRB sufficient to reduce GPCMV titers by 3 logs (50 microM) had no effect on the quantity of GPCMV genomic DNA that was formed in infected cells. Electron microscopy revealed that this DNA was in fact packaged within intranuclear capsids, but these capsids failed to egress from the nucleus and failed to protect the DNA from nuclease digestion. The terminal structure of genomes formed in the presence of BDCRB was also altered. Genomes with ends lacking a terminal repeat at the right end, which normally exist in an equimolar ratio with those having one copy of the repeat at the right end, were selectively eliminated by BDCRB treatment. At the left end, BDCRB treatment appeared to induce heterogeneous truncations such that 2.7 to 4.9 kb of left-end-terminal sequences were missing. These findings suggest that BDCRB induces premature cleavage events that result in truncated genomes packaged within capsids that are permeable to nuclease. Based on these and other observations, we propose a model for duplication of herpesvirus terminal repeats during the cleavage and packaging process that is similar to one proposed for bacteriophage T7 (Y. B. Chung, C. Nardone, and D. C. Hinkle, J. Mol. Biol. 216:939-948, 1990).

Indexed as

AnimalsAntiviral AgentsBenzimidazolesCells, CulturedDNA, ViralGenome, ViralGuinea PigsRibonucleosidesRoseolovirusVirus Assembly2-bromo-5,6-dichloro-1-beta-D-ribofuranosyl benzimidazoleAntiviral AgentsBenzimidazolesDNA, ViralRibonucleosides

Identifiers

PMID14747528
PMCPMC369448
OpenAlexW2168531806

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.